Reduced- Compared with Standard-Dose Direct Oral Anticoagulant for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis
For extended VTE treatment, reduced-dose DOACs have a similar risk of recurrent VTE and a lower risk of major and CRNMB compared to standard dose, including high-risk patients. A potential interaction with sex warrants further investigation.
Authors
- Vinai Bhagirath (ORCID: https://orcid.org/0000-0001-6600-714X)
- Stephanie Carlin (ORCID: https://orcid.org/0000-0003-1111-919X)
- Carmen Ka Man Cheung
- R. Wong
- J. Petropoulos
- Qilong Yi
- John W Eikelboom
- Noel C. C. Chan
- Jeffrey I Weitz
- Thomas C. Scheier
Institutions
- University of Ottawa (CA)
- Population Health Research Institute (CA)
- Prince of Wales Hospital (CN)
- Ottawa Public Health (CA)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Hamilton Health Sciences (CA)
- McMaster University (CA)
Publication Details
- Journal
- TH Open
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1055/a-2798-0066
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Daiichi-Sankyo
- Servier
- LEO Pharma
- Canadian Institutes of Health Research
- Daiichi Sankyo Europe